UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current views of haemolytic streptococcal pathogenesis

Current opinion in infectious diseases, 2014-04, Vol.27 (2), p.155-164

2014

Volltextzugriff (PDF)

Regulation of transforming growth factor β signalling in human B cells by latent Epstein-Barr virus

The Lancet (British edition), 2014-02, Vol.383, p.S46-S46

2014

Volltextzugriff (PDF)

Paraneoplastic pemphigus associated with systemic mastocytosis

American journal of hematology, 2009-12, Vol.84 (12), p.847-848

2009

Volltextzugriff (PDF)

Bronchoscopy in haematopoietic stem cell transplant recipients may not be beneficial

Thorax, 2007-08, Vol.62 (8), p.683-683

Eccersley, Lydia R J

2007

Volltextzugriff (PDF)

Regulation of transforming growth factor ? signalling in human B cells by latent Epstein-Barr virus

The Lancet (British edition), 2014-02, Vol.383, p.S46

2014

Volltextzugriff (PDF)

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients

Clinical infectious diseases, 2022-08, Vol.75 (1), p.178-179

2022

Volltextzugriff (PDF)

Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2024-02, Vol.42 (36_suppl), p.439572-439572

2024

Volltextzugriff (PDF)

Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high‐risk myeloma patients – a single centre experience

British journal of haematology, 2021-04, Vol.193 (2), p.420-423

2021

Volltextzugriff (PDF)

Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study

British journal of haematology, 2021-05, Vol.193 (4), p.750-760

2021

Volltextzugriff (PDF)

The impact of twice-daily consultant ward rounds on the length of stay in two general medical wards – effect on training?

Clinical medicine (London, England), 2012-04, Vol.12 (2), p.186-187

2012

Volltextzugriff (PDF)

MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S568-S568

2024

Volltextzugriff (PDF)

Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S242-S242

2024

Volltextzugriff (PDF)

DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S243-S243

2024

Volltextzugriff (PDF)

MM-557 DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S571-S571

2024

Volltextzugriff (PDF)

P-396 Characterization and Management of Ocular Events in Patients (Pts) Treated With Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S262-S263

2024

Volltextzugriff (PDF)

Posttransplant Lymphoproliferative Disorder of the Thorax: CT and FDG-PET Features in a Single Tertiary Referral Center

Medicine (Baltimore), 2015-08, Vol.94 (31), p.e1274-e1274

2015

Volltextzugriff (PDF)

OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S2-S3

2021

Volltextzugriff (PDF)

Regulation of TGFβ and BMP signalling in human B cells by latent Epstein-Barr virus

Eccersley, Lydia

2014

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(21)
Dissertationen
(1)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Humans
(8)
Hematology
(6)
Male
(4)
Middle Aged
(4)
Multiple Myeloma
(4)
Aged
(3)
Female
(3)
General & Internal Medicine
(3)
Medicine, General & Internal
(3)
Adult
(2)
Animals
(2)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(2)
Biological And Medical Sciences
(2)
Central Nervous System Neoplasms - Drug Therapy
(2)
Dexamethasone
(2)
Epstein-Barr Virus
(2)
Hematologic And Hematopoietic Diseases
(2)
Immunology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Current views of haemolytic streptococcal pathogenesis

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

Regulation of transforming growth factor β signalling in human B cells by latent Epstein-Barr virus

Paraneoplastic pemphigus associated with systemic mastocytosis

Bronchoscopy in haematopoietic stem cell transplant recipients may not be beneficial

Regulation of transforming growth factor ? signalling in human B cells by latent Epstein-Barr virus

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients

Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)

Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high‐risk myeloma patients – a single centre experience

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study

PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study

The impact of twice-daily consultant ward rounds on the length of stay in two general medical wards – effect on training?

MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

MM-557 DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

P-396 Characterization and Management of Ocular Events in Patients (Pts) Treated With Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 Study

Posttransplant Lymphoproliferative Disorder of the Thorax: CT and FDG-PET Features in a Single Tertiary Referral Center

OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)

Regulation of TGFβ and BMP signalling in human B cells by latent Epstein-Barr virus

Suchergebnisse filtern